Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies

Abstract

Recombinant interleukin-2 (rIL-2) is indicated for metastatic renal cell carcinoma and melanoma. Over recent years low-dose rIL-2 has been studied for the treatment of autoimmune diseases and acute coronary syndrome because of its ability to expand and activate T regulatory (T_reg) cells. However, several medical conditions potentially benefiting from rIL-2 administrations are characterized by an intrinsic prothrombotic risk, thus requiring concurrent anticoagulation. In our systematic review of the literature, we investigated the potential for drug interactions between oral anticoagulants and rIL-2 by assessing the influence of rIL-2 administration on transporters and cytochromes determining the pharmacokinetics of (direct) oral anticoagulants. We extracted data from 12 studies, consisting of 11 animal studies and one study in humans. Eight studies investigated the pharmacokinetics of P-glycoprotein (P-gp) substrates and reported that the intraperitoneal rIL-2 administration may inhibit intestinal P-gp. Four studies on hepatic cytochrome P450 yielded conflicting results. The only human study included in this systematic review concluded that rIL-2 suppresses the hepatic cytochrome P450, but only if given at higher doses. Based on the results from animal studies, the co-administration of rIL-2 and dabigatran etexilate, a substrate of intestinal P-gp, may lead to higher dabigatran plasma concentrations and bioavailability. Human studies should confirm whether this potential interaction is clinically relevant.

Keywords

interleukin-2 - drug interaction - oral anticoagulants - systematic review

Authors' Contributions

S.H.M. and S.B. designed the study. S.H.M., M.J., L.V., and S.B. extracted and analyzed the data. S.H.M. and S.B. drafted the manuscript. S.V.K., K.Q., J.D., and C.E.M. critically apprised and revised the manuscript. All authors reviewed the manuscript.

Publication History

Received: 24 July 2019

Accepted: 23 January 2020

Article published online:
23 April 2020

• References

• 1 Rosenzwajg M, Lorenzon R, Cacoub P. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 2019; 78 (02) 209-217
• 2 Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15 (05) 283-294
• 3 Todd JA, Evangelou M, Cutler AJ. et al. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med 2016; 13 (10) e1002139
• 4 Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192 (12) 5451-5458
• 5 Luther N, Shahneh F, Brähler M. et al. Innate effector-memory T-cell activation regulates post-thrombotic vein wall inflammation and thrombus resolution. Circ Res 2016; 119 (12) 1286-1295
• 6 Prochaska JH, Luther N, Brahler M. et al. Acute deep vein thrombosis suppresses peripheral T cell effector function. Br J Haematol 2019; 184 (05) 847-850
• 7 Mahmoudpour SH, Jankowski M, Valerio L. et al. Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. Sci Rep 2019; 9 (01) 7145
• 8 Zhao TX, Kostapanos M, Griffiths C. et al. Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. BMJ Open 2018; 8 (09) e022452
• 9 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
• 10 Carrier M, Blais N, Crowther M. et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 2018; 25 (05) 329-337
• 11 Wang TF, Li A, Garcia D. Managing thrombosis in cancer patients. Res Pract Thromb Haemost 2018; 2 (03) 429-438
• 12 Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 2017; 73 (11) 1417-1425
• 13 Lippi G, Mattiuzzi C, Cervellin G, Favaloro EJ. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann Transl Med 2017; 5 (16) 322
• 14 Yu AYX, Malo S, Svenson LW, Wilton SB, Hill MD. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study. J Am Heart Assoc 2017; 6 (11) e007129
• 15 Testa S, Legnani C, Antonucci E. et al; Coordinator of START2-Register. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2019; 17 (07) 1064-1072
• 16 Testa S, Paoletti O, Legnani C. et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018; 16 (05) 842-848
• 17 Lamb DA, Bungard TJ, Lowerison J. et al. Jurisdictional guidance on DOAC use-will it affect practice? A comparison of European, American, and Canadian product monographs. Ann Pharmacother 2020; 54 (03) 277-282
• 18 Chang SH, Chou IJ, Yeh YH. et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318 (13) 1250-1259
• 19 Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev 2018; 7 (01) 55-61
• 20 Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013; 11 (01) 10
• 21 Gelosa P, Castiglioni L, Tenconi M. et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018; 135: 60-79
• 22 Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76 (03) 455-466
• 23 Di Minno A, Frigerio B, Spadarella G. et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev 2017; 31 (04) 193-203
• 24 Mendell J, Zahir H, Matsushima N. et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13 (05) 331-342
• 25 Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 2016; 55 (06) 641-655
• 26 Abbara C, Rouchon C, Hosten B, Farinotti R, Bonhomme-Faivre L. Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. Drug Metabol Drug Interact 2004; 20 (04) 219-231
• 27 Bonhomme-Faivre L, Pelloquin A, Tardivel S. et al. Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anticancer Drugs 2002; 13 (01) 51-57
• 28 Cantoni L, Carelli M, Ghezzi P, Delgado R, Faggioni R, Rizzardini M. Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. Eur J Pharmacol 1995; 292 (3-4): 257-263
• 29 Castagne V, Bonhomme-Faivre L, Urien S. et al. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. Drug Metab Dispos 2004; 32 (02) 168-171
• 30 Elkahwaji J, Robin MA, Berson A. et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999; 57 (08) 951-954
• 31 Hosten B, Abbara C, Cibert M. et al. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs 2010; 21 (02) 193-201
• 32 Hosten B, Abbara C, Petit B. et al. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice. Drug Metab Dispos 2008; 36 (08) 1729-1735
• 33 Hosten B, Challuau D, Gil S. et al. Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma. Anticancer Drugs 2006; 17 (02) 195-199
• 34 Jamois C, Comets E, Mentré F, Marion S, Farinotti R, Bonhomme-Faivre L. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. Cancer Chemother Pharmacol 2005; 55 (01) 61-71
• 35 Kurokohchi K, Matsuo Y, Yoneyama H, Nishioka M, Ichikawa Y. Interleukin 2 induction of cytochrome P450-linked monooxygenase systems of rat liver microsomes. Biochem Pharmacol 1993; 45 (03) 585-592
• 36 Thal C, el Kahwaji J, Loeper J. et al. Administration of high doses of human recombinant interleukin-2 decreases the expression of several cytochromes P-450 in the rat. J Pharmacol Exp Ther 1994; 268 (01) 515-521
• 37 Veau C, Faivre L, Tardivel S. et al. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 2002; 302 (02) 742-750
• 38 Novartis Pharmaceuticals Canada Inc. Product Monograph Proleukin (Aldesleukin) Interleukin-2 Lyophilized Powder 22 Million IU/Vial. Date of approval 25 July 2018
• 39 Delavenne X, Ollier E, Basset T. et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76 (01) 107-113
• 40 Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos 2014; 42 (02) 257-263
• 41 Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013; 75 (04) 1053-1062
• 42 Barco S, Coppens M, van den Dool EJ, van de Kerkhof D, Stroobants AK, Middeldorp S. Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation. Thromb Haemost 2014; 112 (04) 836-838
• 43 Kumar P, Gordon LA, Brooks KM. et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother 2017; 61 (11) e01201-17
• 44 Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011; 338 (01) 372-380
• 45 Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 2013; 9 (03) 237-252